NCT04173065Phase 2Completed

A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH

Study sponsor: Viking Therapeutics, Inc. · VKTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-05-15Actual
Enrollment · participants248Actual
Source updated2024-06-14Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview